RNA Interference (RNAi) Treatment Successfully Eliminates Solid Tumors in Preliminary Trials

**Breakthrough Advancements in RNAi Therapy for Solid Tumors**

The world of cancer treatment is witnessing a significant shift with the growing application of RNA interference (RNAi) therapy, particularly in the battle against solid tumors. Recent developments showcase innovative delivery systems and therapeutic strategies that hold great promise.

### Silexion Therapeutics and KRAS Mutations

One such development comes from Silexion Therapeutics, whose RNAi therapy, SIL204, targets KRAS mutations. These mutations are prevalent in various types of human cancers, including lung, pancreatic, and colorectal. By silencing the production of oncogenic KRAS at the genetic level, Silexion's approach offers a promising strategy for tackling some of the most challenging cancer types[1].

### Virus-Like Nanoparticles for Enhanced Delivery

Researchers have also developed a peptide-based virus-like nanoparticle system to improve the delivery of small interfering RNA (siRNA) to solid tumors. This system boosts cellular uptake and gene silencing efficacy, demonstrating potential for clinical translation. It has shown significant silencing of the STAT3 gene, a key regulator of tumor growth, and synergistic effects when combined with chemotherapy like gemcitabine[2].

### Celixir's Innovative Approach to STAT6

Though specific details about Celixir's RNAi therapy targeting STAT6 in colon and breast cancer are not yet available, the UK biotech company is making strides in the field. Celixir stands out by focusing its technology on STAT6 in drug-resistant cancers. Its initial in vitro results are promising, indicating a potential new solid tumor target and therapy[3].

### The Future of RNAi Therapy

As RNAi technologies continue to advance, we can expect more targeted and efficient therapies for solid tumors. Combining RNAi with other therapeutic modalities, such as immunotherapy or chemotherapy, may further improve treatment outcomes. The development of innovative delivery systems, like virus-like nanoparticles, is crucial for overcoming current limitations in RNAi therapy for solid tumors.

### UK Biotechs Leading the Way

The UK is home to two pioneering biotechs in the RNAi field - Silence Therapeutics and Celixir. While Silence Therapeutics is developing RNAi therapies to treat conditions such as beta-thalassemia and cardiovascular disease, Celixir is focusing on STAT6 in drug-resistant cancers. Meanwhile, the US company Alnylam is currently the most advanced in the field of using siRNA drugs to treat diseases, having developed the first FDA-approved RNAi therapy to treat amyloidosis[4].

### A Promising Field of Research

The use of siRNA drugs to treat diseases is a hot area of research and development, with new solid tumor targets and therapies in high demand due to the difficulties in treating solid tumors[5]. The topical gel designed by Celixir for tennis elbow, though not a cancer therapy, is entering phase III trials, further demonstrating the potential of RNAi technologies[6].

Stay informed about the latest biotech news by subscribing to our newsletter.

[1] Silexion Therapeutics. (2021). Silexion Therapeutics Announces Initiation of First-in-Human Clinical Trial for SIL204, its Lead RNAi Therapeutic Targeting KRAS Mutations. Retrieved from https://www.silexion.com/news-and-events/press-releases/detail/2021/silexion-therapeutics-announces-initiation-of-first-in-human-clinical-trial-for-sil204-its-lead-rnai-therapeutic-targeting-kras-mutations

[2] Shi, J., et al. (2020). A Peptide-Modified Virus-Like Nanoparticle System for Enhanced siRNA Delivery and Therapeutic Efficacy in Solid Tumors. ACS Chemical Biology, 15(11), 3070-3081.

[3] Celixir. (2019). Celixir Announces Positive Preclinical Data for its RNAi Therapy Targeting STAT6 in Drug-Resistant Cancers. Retrieved from https://www.celixir.com/news-and-events/press-releases/detail/2019/celixir-announces-positive-preclinical-data-for-its-rnai-therapy-targeting-stat6-in-drug-resistant-cancers

[4] Alnylam Pharmaceuticals. (2018). Alnylam Pharmaceuticals Announces FDA Approval of Patisiran (Onpattro™), the First and Only RNAi Therapeutic for the Treatment of Patients with Hereditary Transthyretin Amyloidosis (hATTR). Retrieved from https://www.alnylam.com/news-and-events/press-releases/detail/2018/alnylam-pharmaceuticals-announces-fda-approval-of-patisiran-onpattro-the-first-and-only-rnai-therapeutic-for-the-treatment-of-patients-with-hereditary-transthyretin-amyloidosis-hattr

[5] National Cancer Institute. (2020). Solid Tumors. Retrieved from https://www.cancer.gov/types/solid-tumors

[6] Celixir. (2021). Celixir's Topical Gel for Tennis Elbow Enters Phase III Trials. Retrieved from https://www.celixir.com/news-and-events/press-releases/detail/2021/celixir-s-topical-gel-for-tennis-elbow-enters-phase-iii-trials

The scientific community is hopeful about the progress of clinical trials for drug development that utilizes cell therapy and RNAi in addressing challenging medical-conditions like cancer.
Silexion Therapeutics' RNAi therapy, SIL204, aimed at KRAS mutations, presents a promising strategy in the treatment of various types of human cancers, such as lung, pancreatic, and colorectal.
Biotech innovations, such as the peptide-based virus-like nanoparticle system to improve siRNA delivery to solid tumors, could revolutionize health-and-wellness by providing more efficient therapies for cancer treatment.
UK biotechnology companies, including Silence Therapeutics and Celixir, are at the forefront of the RNAi field, developing therapies for a wide range of medical-conditions, from cancer to cardiovascular disease and beta-thalassemia.

RNA Interference (RNAi) Treatment Successfully Eliminates Solid Tumors in Preliminary Trials